Lymphoma, Extranodal NK-T-Cell: all 185 studies
Page 2 of 2. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.
- A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive MalignanciesStatus unknownNCT03789617Phase 1/2
- VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma PatientsStatus unknownNCT03671850Phase 2
- AEDV Registry of Primary Cutaneous LymphomaStatus unknownNCT03646422
- Tofacitinib Combined With Chidamide in R/R ENKTCLStatus unknownNCT03598959Phase 2
- Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell LymphomasWithdrawnNCT03586024Phase 1/2
- Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]Status unknownNCT03439501Phase 2
- SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell LymphomaStatus unknownNCT03363555Phase 2
- B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell LymphomaCompletedNCT03246750Phase 1/2
- GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell LymphomaStatus unknownNCT03154918Phase 2
- Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL PatientsCompletedNCT03079544
- 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell LymphomaStatus unknownNCT03051555Not applicable
- Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell LymphomaStatus unknownNCT03051542Not applicable
- Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus ActivationStatus unknownNCT02878278Phase 2
- Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell LymphomaCompletedNCT02825147Phase 2
- Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell LymphomaTerminatedNCT02808091Phase 2
- MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell LymphomaCompletedNCT02764281Not applicable
- CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaStatus unknownNCT02742727Phase 1/2
- GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell LymphomaCompletedNCT02733458Not applicable
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- MESA Versus ESA in the Treatment of Early Stage NK/T-cell LymphomaStatus unknownNCT02631239Phase 3
- Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeStatus unknownNCT02560441Phase 2
- VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)Status unknownNCT02544425Phase 2
- P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma PatiensTerminatedNCT02533323Phase 2
- International Extranodal NK/T-cell Lymphoma ProjectCompletedNCT02386813
- Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early StageTerminatedNCT02359162Phase 3
- Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell LymphomaCompletedNCT02276248Phase 2
- Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX ChemotherapyStatus unknownNCT02229682Phase 2
- CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1
- PEG-ASP+Gemox Regimen and Thalidomide for NK/T LymphomaStatus unknownNCT02085655Phase 3
- Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTLStatus unknownNCT02080234Phase 2
- GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell LymphomaStatus unknownNCT01991158Phase 2
- Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
- Cellular Immunotherapy Treatment Antigen-Directed for EBV LymphomaTerminatedNCT01948180Phase 2
- MESA Treatment for NK/T Cell LymphomaStatus unknownNCT01933282Phase 2
- Avastin+ GemAOD As First-Line Treatment in NK/T Cell LymphomaStatus unknownNCT01921790Phase 2
- Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyActive, not recruitingNCT01787409Not applicable
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
- MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
- Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell LymphomaStatus unknownNCT01667302Phase 2
- Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell LymphomaTerminatedNCT01667289Phase 2
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
- Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell LymphomaCompletedNCT01341119
- Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01336920Phase 1
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell LymphomaCompletedNCT01238159Phase 2
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell LymphomaCompletedNCT01192984Phase 2
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
- Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01129180Phase 1
- Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1
- Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaTerminatedNCT00933985Phase 1
- Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell LymphomaCompletedNCT00901147Phase 2
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT00891072Phase 1
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- FAU in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00769288Phase 1
- Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOPStatus unknownNCT00725231Phase 3
- Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
- Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell LymphomaStatus unknownNCT00568607Phase 2
- Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver DysfunctionCompletedNCT00499811Phase 1
- Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
- PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
- PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasCompletedNCT00348985Phase 1
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell LymphomaActive, not recruitingNCT00336063Phase 1
- Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
- SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaTerminatedNCT00101244Phase 1
- Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaTerminatedNCT00101205Phase 1
- MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedNCT00098891Phase 1
- Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
- Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
- Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
- Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesCompletedNCT00014235Not applicable
- Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic CancerCompletedNCT00006251Phase 1/2
- Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple MyelomaCompletedNCT00003196Not applicable